What role does the heme— heme oxygenase—carbon monoxide system play in vasoregulation?

Authors:

Abstract
In our original study, we suggested that because CO shared the ability of NO to activate soluble guanylyl cyclase (sGC), CO would exert its physiological effects by activating sGC (7). Our proposal has been criticized because CO is considerably less potent than NO in activating sGC (1). This criticism has been muted by a number of observations; thus a synthetic chemical, YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole], an NO-independent activator of sGC, potentiates CO stimulation of the activity of this enzyme to a magnitude similar to that achieved by NO (3). The existence of an endogenous functional analog of YC-1 would greatly strengthen the concept of a physiological role for CO (3). The recent observations that bilirubin and biliverdin potentiate the relaxant effects of CO in the guinea pig fundus may be relevant in this regard. Biliverdin and bilirubin are produced by the nitrergic neurons of this preparation concomitantly with CO by HO and might be endogenous functional analogs of the synthetic drug YC-1 (2). Wang et al. (11) showed that in precontracted rat tail artery, CO produced its vasorelaxant effect both by activation of sGC and by opening of high conductance KCa channels. The involvement of KCa channels in CO-induced vasorelaxation has been confirmed by others (5, 12). Further important physiological effects of CO, namely anti-inflammatory and antiapoptotic effects, have been shown to be due to modulation of the p38 mitogen-activated protein kinase (MAPK) signaling pathway (9). These observations demonstrate that sGC activation is not the only mechanism by which CO can act and that earlier estimates of CO potency on sGC may have been too conservative.

This publication has 12 references indexed in Scilit: